Chronic Obstructive Pulmonary Disease Case Finding in Community-pharmacies by Spirometry (FARMAEPOC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01576068|
Recruitment Status : Unknown
Verified April 2012 by Col·legi de Farmacèutics de la Província de Barcelona.
Recruitment status was: Active, not recruiting
First Posted : April 12, 2012
Last Update Posted : April 12, 2012
Chronic Obstructive Pulmonary Disease (COPD) is a prevalent disease. In the investigators country, underdiagnosis has been estimated in around 80% of subjects. Early detection is done mainly in primary care but due to actual situation new alternatives have been proposed to decrease underdiagnosis.
This present study promote by a multidisciplinary research team (respiratory medicine, primary care, nurse and pharmacist) raise the objective of evaluate the effect of a COPD case finding program guide by spirometry in community-pharmacies.
From the results of a pilot-study conducted in 13 community-pharmacies in Barcelona, in which the investigators showed the feasibility of spirometry in community-pharmacies for the early detection of COPD, the investigators have design a second phase to evaluate the effect of this strategy. 100 Barcelona's community-pharmacies during 6 months will select high risk customers and will conduct a spirometry in agreement with the design protocol. 3600 spirometries is the establish objective. Participants hospitals will train pharmacist in spirometry and also control spirometry quality daily by a telematic pathway. Spirometry results will be evaluate in terms of effect and costs. The investigators will also evaluate the impact of this program in the health system by numbers of subjects diagnosed and follow up in primary care.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Obstructive Pulmonary Disease||Other: Spirometry||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||3600 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficiency of COPD Case Finding Program by Spirometry in High-risk Customers of Urban Community Pharmacies|
|Study Start Date :||October 2010|
|Estimated Primary Completion Date :||July 2012|
|Estimated Study Completion Date :||June 2013|
High Risk Customers
Pharmacy customers with GOLD COPD Criteria of high-risk subjects.
Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation
- COPD Case Finding [ Time Frame: During 15 months pharmacies will include subjects with possible COPD through spirometry. ]Proportion of high-risk customers with spirometry showing a FEV1/FVC under 0,7.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01576068
|Col·legi Oficial de Farmacèutics de Barcelona|
|Barcelona, Spain, 08009|
|Principal Investigator:||Diego Castillo, MD||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|